Skyhawk Therapeutics expands licensing partnership with Biogen
Category: #health  By Pankaj Singh  Date: 2019-07-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Skyhawk Therapeutics expands licensing partnership with Biogen

Skyhawk Therapeutics, Inc. has recently announced the expansion of its partnership with Biogen, which was initially announced on January 4, 2019.

The expansion, which leverages on the breadth of SkySTAR™ technology platform from Skyhawk, apparently expands the exclusive license of Biogen to global intellectual property rights beyond the original alliance’s research-stage therapeutic candidates for the treatment of conditions including spinal muscular atrophy, multiple sclerosis, and additional neurological disorders.

Sources familiar with the matter informed that under the agreement, Skyhawk would receive an upfront payment from Biogen and could benefit from potential future milestone royalties and payments.

According to chief executive officer and co-founder of Skyhawk, Bill Haney, Biogen has a compelling history of drug development across a multiple range of challenging conditions. The strong scientific culture of the company has already created a series of prominent global therapeutics and the work together till date has gone extremely well. Skyhawk would expand the opportunity to work together for helping more patients with challenging unmet medical requirements, Haney added.

For the uninitiated, Skyhawk Therapeutics is focused towards developing, discovering, and commercializing therapies that use its new SkySTAR™ platform to generate small molecule drugs that deliver advanced treatments to patients.

Sources further mentioned that Merck & Co. Inc., the USA based multinational pharmaceutical company, has reportedly selected Skyhawk Therapeutics for its proficiency in the development and discovery of small molecules which modulate RNA splicing. It has agreed to finance it up to $600 million for each program target along with royalties on sales of any commercialized products resulting from their partnership.

Seemingly, the agreement would be focused on potential treatments for cancer and certain neurological diseases. The agreement would mark the first external oncology partnership of Skyhawk following two years of work on its own internal oncology target, representing a careful move into the space for which it recruited new key talents.

Source Credits: https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-expansion-of-collaboration-agreement-with-biogen-300880506.html

http://www.bioworld.com/content/skyhawk-lands-new-rna-focused-deal-merck



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...